United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline 0.5 mg

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline 0.5 mg

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - cabergoline 0,5 mg - tablet - 0,5 mg - cabergoline 0.5 mg - cabergoline

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - cabergoline 0.5mg - tablet - 0.5 mg - active: cabergoline 0.5mg excipient: lactose magnesium stearate - indicated for the inhibition of physiological lactation soon after delivery. (1) after parturition, when breast feeding is contraindicated due to medical reasons related to the mother or the new-born. (2) after still birth or abortion.

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - cabergoline - tablets - cabergoline 0.5 mg - cabergoline - cabergoline - treatment of hyperprolactinemic disorders.dostinex is indicated for the treatment of dysfunctions associated with hyperprolactinemia, including amenorrhea, oligomenorrhea, anovulation and galactorrhea. dostinex is indicated in patients with prolactin-secreting pituitary adenomas (micro-and macroprolactinomas), idiopathic hyperprolactinemia, or empty sella syndrome with associated hyperprolactinemia. inhibition and supression of lactation .

Canada - English - Health Canada

teva canada limited - cabergoline - tablet - 0.5mg - cabergoline 0.5mg - ergot-derivative dopamine receptor agonists

United States - English - NLM (National Library of Medicine)

a-s medication solutions - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets are contraindicated in patients with: - uncontrolled hypertension or known hypersensitivity to ergot derivatives. - history of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis (see warnings ). - history of pulmonary, pericardial, or retroperitoneal fibrotic disorders (see warnings ).

United States - English - NLM (National Library of Medicine)

a-s medication solutions - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets are contraindicated in patients with: - uncontrolled hypertension or known hypersensitivity to ergot derivatives. - history of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis (see warnings). - history of pulmonary, pericardial, or retroperitoneal fibrotic disorders (see warnings).

United States - English - NLM (National Library of Medicine)

a-s medication solutions - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline tablets, usp are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. cabergoline tablets, usp are contraindicated in patients with: - uncontrolled hypertension or known hypersensitivity to ergot derivatives. - history of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis. (see warnings ) - history of pulmonary, pericardial, or retroperitoneal fibrotic disorders. (see warnings )

United States - English - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - cabergoline (unii: ll60k9j05t) (cabergoline - unii:ll60k9j05t) - cabergoline tablets, usp are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas cabergoline tablets, usp are contraindicated in patients with - uncontrolled hypertension or known hypersensitivity to ergot derivatives. - history of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve, determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis (see warnings ). - history of pulmonary, pericardial, or retroperitoneal fibrotic disorders (see warnings ).